Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
TQB-2825 in T-cell/histiocyte rich large B-cell lymphoma: NCT06829771 Clinical Landscape Report 2026
15 October 2026
NCT06829771 clinical landscape for T-cell/histiocyte rich large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
C402-CD19-CAR in High grade B-cell lymphoma: NCT06830031 Clinical Landscape Report 2026
15 October 2026
NCT06830031 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Triple Negative Breast Cancer: NCT06829199 Clinical Landscape Report 2026
15 October 2026
NCT06829199 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abemaciclib in Metastatic Renal Cell Carcinoma: NCT06835972 Clinical Landscape Report 2026
15 October 2026
NCT06835972 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mosunetuzumab in Diffuse Large B-Cell Lymphoma: NCT06828991 Clinical Landscape Report 2026
15 October 2026
NCT06828991 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Diffuse Large B-Cell Lymphoma: NCT06832267 Clinical Landscape Report 2026
15 October 2026
NCT06832267 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rituximab biosimilar(Hualan Genetic Engineering Co Ltd) in Diffuse Large B-Cell Lymphoma: NCT06832228 Clinical Landscape Report 2026
15 October 2026
NCT06832228 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CAR2219 CAR-T Cells(Affiliated Hospital to Academy of Military Medical Sciences) in B-Cell Leukemia: NCT06834529 Clinical Landscape Report 2026
15 October 2026
NCT06834529 clinical landscape for B-Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SCTB-35 in Systemic Lupus Erythematosus: NCT06841042 Clinical Landscape Report 2026
15 October 2026
NCT06841042 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Golcadomide Hydrochloride in Diffuse Large B-Cell Lymphoma: NCT06835530 Clinical Landscape Report 2026
15 October 2026
NCT06835530 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GD2/B7H3 CAR T-cell therapy(Yake Biotechnology) in Refractory Neuroblastoma: NCT06836505 Clinical Landscape Report 2026
15 October 2026
NCT06836505 clinical landscape for Refractory Neuroblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dacarbazine in Soft Tissue Sarcoma: NCT06835049 Clinical Landscape Report 2026
15 October 2026
NCT06835049 clinical landscape for Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.